---
title: "Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Specific populations questions"
description: "Specific populations questions on Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: Can Vyndamax be used during pregnancy? Can Vyndamax be used while breastfeeding? Can children take Vyndamax? Does Vyndamax need a dose adjustment for older adults? 2 further questions follow. 6 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Specific populations questions

Manufacturer: Pfizer Inc  
Prescribing information: [Vyndaqel and Vyndamax](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685)

## Pregnancy and breastfeeding

<a id="vyndamax-pregnancy"></a>

### Can Vyndamax be used during pregnancy?

> “Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman. However, limited available human data with VYNDAQEL use in pregnant women (at a dose of 20 mg per day) have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Based%20on%20findings%20from%20animal,adverse%20maternal%20or%20fetal%20outcomes.)

> “Advise pregnant women of the potential risk to a fetus. Report pregnancies to the Pfizer reporting line at 1-800-438-1985.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Advise%20pregnant%20women%20of%20the,Pfizer%20reporting%20line%20at%201%2D800%2D438%2D1985.)

> “Consider pregnancy planning and prevention for females of reproductive potential.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Consider%20pregnancy%20planning%20and%20prevention%20for%20females%20of%20reproductive%20potential.)

<a id="vyndamax-breastfeeding"></a>

### Can Vyndamax be used while breastfeeding?

> “There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk (see Data). When a drug is present in animal milk, it is likely the drug will be present in human milk. Based on findings from animal studies which suggest the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with VYNDAQEL or VYNDAMAX.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=There%20are%20no%20available%20data,treatment%20with%20VYNDAQEL%20or%20VYNDAMAX.)

## Pediatric use

<a id="vyndamax-children"></a>

### Can children take Vyndamax?

> “The safety and effectiveness of VYNDAQEL and VYNDAMAX have not been established in pediatric patients.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20safety%20and%20effectiveness%20of,been%20established%20in%20pediatric%20patients.)

## Specific populations

<a id="vyndamax-older-adults"></a>

### Does Vyndamax need a dose adjustment for older adults?

> “No dosage adjustment is required for elderly patients (≥65 years) [see Clinical Pharmacology (12.3)]. Of the total number of patients in the clinical study (n=441), 90.5% were 65 and over, with a median age of 75 years.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=No%20dosage%20adjustment%20is%20required,median%20age%20of%2075%20years.)

<a id="vyndamax-kidney-liver"></a>

### Do kidney or liver problems change Vyndamax levels in the body?

> “No clinically significant differences in the pharmacokinetics of tafamidis were observed based on age, race/ethnicity (Caucasian and Japanese) or renal impairment.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Specific%20Populations-,No%20clinically%20significant%20differences%20in%20the%20pharmacokinetics%20of%20tafamidis%20were,and%20Japanese%29%20or%20renal%20impairment.)

> “Patients with moderate hepatic impairment (Child-Pugh Score of 7 to 9) had decreased systemic exposure (approximately 40%) and increased clearance (approximately 68%) of tafamidis compared to healthy subjects. As TTR levels are lower in subjects with moderate hepatic impairment than in healthy subjects, the exposure of tafamidis relative to the amount of TTR is sufficient to maintain stabilization of the TTR tetramer in these patients. No clinically significant differences in the pharmacokinetics of tafamidis were observed in patients with mild hepatic impairment (Child Pugh Score of 5 to 6) compared to healthy subjects. The effect of severe hepatic impairment on tafamidis is unknown.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Patients%20with%20moderate%20hepatic%20impairment,impairment%20on%20tafamidis%20is%20unknown.)

> “Before taking VYNDAQEL or VYNDAMAX, tell your healthcare provider about all your medical conditions, including if you:
>
> •
> have liver problems.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Before%20taking%20VYNDAQEL%20or%20VYNDAMAX%2C,have%20liver%20problems.)

Note: The last passage is from the FDA-approved Patient Information printed with the label.

<a id="vyndamax-overdose"></a>

### What is known about Vyndamax overdose?

> “There is minimal clinical experience with overdose. During clinical trials, two patients accidentally ingested a single VYNDAQEL dose of 160 mg without adverse events. The highest dose of tafamidis meglumine given to healthy volunteers in a clinical trial was 480 mg as a single dose. There was one reported adverse event of mild hordeolum at this dose.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=There%20is%20minimal%20clinical%20experience,mild%20hordeolum%20at%20this%20dose.)

## Related pages
- [Medical information: Vyndamax (tafamidis): Transthyretin amyloid cardiomyopathy](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy)
- [Indication](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/guidelines)
